To assess the potential of A-SAA as an HCC biomarker, a total of 166 patients were prospectively enrolled, and they were categorized into three groups: hepatitis (n = 40), LC (n = 30), and HCC (n = 96). This evidence concerns the gene SAA1 and laryngotracheoesophageal cleft.